PDCD1 and neoplasm: We also propose that probing a wide panel of syngeneic models and their unique tumor microenvironments with a given immunotherapy will yield insights into features (such as TIL+PD-L1+ for anti-PD1) that define responding versus non-responding tumors in humans.